诺和终止2.85亿美元合作,近两年在月度GLP-1赛道三度折戟

每日经济新闻
Yesterday

两家丹麦制药企业终止了近两年的合作协议。  9月14日,Ascendis Pharma(Nasdaq:ASND)宣布,诺和(诺和诺德于2026年9月15日启用的统一品牌名称)已终止双方于2024年11月达成的代谢与心血管疾病合作协议。  协议终止后,Ascendis将收回TransCon技术在代谢与心血管疾病领域的全部权益,包括领跑项目——每月注射一次的TransCon司美格鲁肽,双方均不再承担...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10